ArticleEuropean journal of heart failure2011
Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry.
Article in European journal of heart failure, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta-analysis.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2020Pooled it
- Identifying and characterizing commercially insured patients with HFpEF with high vs low health care resource utilization.Journal of managed care & specialty pharmacy · 2025Article
- Molecular Mechanism of Yangshen Maidong Decoction in the Treatment of Chronic Heart Failure based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations.Cell biochemistry and biophysics · 2024Article
- Impact of Cardiac Troponin Elevation on Mortality of Patients with Acute Heart Failure: Insights from the Korea Acute Heart Failure (KorAHF) Registry.Journal of clinical medicine · 2022Article
- Current status of heart failure: global and Korea.The Korean journal of internal medicine · 2020Review
- Rate of Rehospitalization in 60 Days of Discharge and It's Determinants in Patients with Heart Failure with Reduced Ejection Fraction in a Tertiary Care Centre in India.International journal of heart failure · 2020Article
- The role of M-mode echocardiography in patients with heart failure and preserved ejection fraction: A prospective cohort study.Experimental and therapeutic medicine · 2020Article
- Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group?International journal of cardiology. Heart & vasculature · 2018Article
- The China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective heart failure study design.BMJ open · 2018Article
- Patients Characteristics and Preliminary Outcomes of Heart Failure Registry in A Middle-Income Country: Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF).Galen medical journal · 2018Article
- Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF).Korean circulation journal · 2017Article
- Comprehensive healthcare resource use among newly diagnosed congestive heart failure.Israel journal of health policy research · 2017Article
- Heart Failure: Diagnosis, Management and Utilization.Journal of clinical medicine · 2016Review
- Breakthrough in heart failure with preserved ejection fraction: are we there yet?The Korean journal of internal medicine · 2016Review
- Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction.Heart and vessels · 2015Article
- Understanding the epidemic of heart failure: past, present, and future.Current heart failure reports · 2014Review
- Outcomes in acute heart failure: 30-day readmission versus death.Current heart failure reports · 2014Article
- Epidemiology of heart failure with preserved ejection fraction.Current heart failure reports · 2014Review
- Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.American heart journal · 2014Article
- Epidemiology of heart failure.Circulation research · 2013Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
aimsTo characterize geographic differences in clinical characteristics and care of patients hospitalized with heart failure and preserved ejection fraction (HF-PEF). METHODS AND
resultsUsing data on 61 182 admissions in 307 US hospitals from March 2004 to March 2006 from the Acute Decompensated Heart Failure National Registry (ADHERE)-United States (US) database and 10 904 admissions in 70 hospitals from 10 countries from March 2005 to January 2009 from the ADHERE-International (I) database composed of countries in Asia-Pacific and Latin-American regions, we compared characteristics, treatments, length of stay, and in-hospital mortality between patients with PEF (left ventricular EF ≥ 40%). There were 26 258 (49.6%) admissions with HF-PEF in the ADHERE-US and 4206 (45.7%) in ADHERE-I. The USA cohort was older [median 77.2 years (25th, 75th, 66.5, and 84.4) vs. 71.0 (59.0, 79.0), P< 0.001] and more likely to be female (61.8 vs. 54.7%, P< 0.001). The international cohort had a longer length of stay [median 6.0 days (4.0, 10.0)] vs. 4.0 days [3.0, 7.0], P< 0.001) and higher use of inotropes (12.5 vs. 4.8%, P< 0.001). At discharge, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and diuretics were prescribed more in the USA (57.6 vs. 54.4%, P< 0.001; 63.0 vs. 35.5%, P< 0.001; 78.2 vs. 76.2%, P< 0.001); digoxin was prescribed more outside the USA (26.0 vs. 17.7%, P< 0.001). After adjusting for baseline characteristics, 7-day inpatient mortality was similar between the international and the USA cohorts [hazard ratio 0.80, 95% CI (0.61-1.05); P= 0.11].
conclusionsClinical characteristics, inpatient interventions, discharge therapies, and length of stay vary significantly for HF-PEF patients across geographic regions. This has important implications for global clinical trials and outcome studies in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.